Seeking Alpha

GSK gives up on MAGE-A3 for lung cancer

  • GlaxoSmithKline (GSK) has ended Phase III testing of its MAGE-A3 lung-cancer vaccine after failing to find a sub-group of patients who could benefit from the therapy.
  • GSK's move comes less than two weeks after MAGE-A3 failed in the overall trial, which tested the drug for non-small cell lung cancer.
  • GSK will continue to research the benefits of MAGE-A3 for melanoma in sub-populations after the drug failed in an overall study of subjects with this type of cancer.
  • MAGE-A3 was designed to help the immune systems of cancer patients prevent the return of the disease after surgery.
  • GSK's stock is -0.5%.
  • Shares in Agenus (AGEN), whose QS-21 Stimulon adjuvant, or booster, is used in MAGE-A3, are -9.4%. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: